BEIJING, Dec. 28(Xinhua) -- GeneQuantum Healthcare (GQ), a global innovative biotechnology company dedicated to the development of the next generation bioconjugate drugs, and WuXi XDC, a joint venture established by WuXi Biologics and WuXi STA which provides end-to-end contract research, development and manufacturing of bioconjugates, announced their strategic cooperation for conjugation technology licensing and ADC drug development on Monday, reported Shanghai Securities News.
According to the agreement, Wuxi XDC will actively promote GeneQuantum's proprietary iLDC (intelligent Ligase-dependent Conjugation) and iGDC (intelligent Glycotransferase-dependent conjugation) platforms around the globe to empower innovative bioconjugate development and the commercial production for drug developers.
Based on WuXi XDC 's leading ADC production platform and integrated CMC capability, GeneQuantum will also develop multiple ADC drugs through collaboration with Wuxi XDC, and foresee accelerated product commercialization.
Through years of interdisciplinary and differentiated innovation, GeneQuantum has developed iLDC and iGDC platforms as the core technology of bioconjugate drug. To address growing interest and opportunities for bioconjugate drugs globally, the company will work closely with its partners, empower its innovative conjugation technologies for the development of bioconjugate drugs and promote the conjugation technology ecosystem to bring more safe, more efficient and more accessible innovative conjugate drugs to patients around the world, according to Gang Qin, Founder and Chairman of GQ.
New and innovative ideas and technologies have emerged in the field of bioconjugate drugs represented by ADC, which has become a hot spot of investment and drug development, said Jimmy Lee, CEO of Wuxi XDC.
(Edited by Gao Jingyan with Xinhua Silk Road, gaojingyan@xinhua.org)
A single purchase
